Ken Griffin Atea Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$3.31 - $4.04 $34,093 - $41,612	-10,300 Reduced 78.63%	2,800 $9,000
Q1 2024 May 15, 2024	SELL	$3.09 - $4.56 $2,781 - $4,104	-900 Reduced 6.43%	13,100 $52,000
Q4 2023 Feb 14, 2024	SELL	$2.8 - $3.35 $4,480 - $5,360	-1,600 Reduced 10.26%	14,000 $42,000
Q3 2023 Nov 14, 2023	SELL	$3.0 - $3.79 $600 - $758	-200 Reduced 1.27%	15,600 $46,000
Q2 2023 Aug 14, 2023	SELL	$3.21 - $5.06 $23,754 - $37,444	-7,400 Reduced 31.9%	15,800 $59,000
Q1 2023 May 15, 2023	SELL	$3.0 - $4.97 $138,600 - $229,614	-46,200 Reduced 66.57%	23,200 $77,000
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.17 $571,155 - $810,121	-131,300 Reduced 65.42%	69,400 $333,000
Q3 2022 Nov 14, 2022	SELL	$5.49 - $8.79 $38,979 - $62,408	-7,100 Reduced 3.42%	200,700 $1.14 Million

111

51.2M

71.8K

318K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $301M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.